CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that preclinical data from its oncology program, EDP1503, will be presented during the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting being held November 6–10, 2019 in National Harbor, Maryland.
Details of the accepted abstract are as follows:
Title: Monoclonal microbial EDP1503 induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity
Poster Session Date & Time: Friday, November 8, 2019, 7:00 a.m. – 8:00 p.m. (EST)
Poster Session: Regular and Young Investigator Award Posters
Authors: Humphrey A. Gardner, MD; Michael Goldberg, PhD; Shubhra Kashyap, MS; Holly Ponichtera, PhD; Peter Sandy, PhD; Shannon Argueta, PhD; Chris Davitt, PhD; Mark Carlson, MS; Maria Sizova, PhD; Valeria Kravitz, MS; Erin Troy, PhD; Sam Andrewes, MS; Mark Bodmer, PhD; Loise Francisco-Anderson, PhD
The accepted abstract is listed below and available online on the SITC conference website: https://sitc.sitcancer.org/2019/abstracts/titles/index.php?filter=EDP1503.
About Evelo Biosciences
Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects. These cells in the small intestine play a central role in governing the immune, metabolic and neurological systems. The company’s first product candidates are monoclonal microbials, single strains of microbes selected for defined pharmacological properties. They have been observed in preclinical models to have systemic dose-dependent effects, modulating multiple clinically validated pathways. Evelo’s therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with chronic disease and cancer.
Evelo currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas.
For more information, please visit www.evelobio.com.
Jessica Cotrone, 978-760-5622
Source: Evelo Biosciences, Inc.